Minerva Neurosciences Inc
Company Profile
Business description
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
Contact
1500 District Avenue
BurlingtonMA01803
USAT: +1 617 600-7373
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
7
Stocks News & Analysis
stocks
ASX top pick remains cheap despite weaker consumer confidence
stocks
Chart of the Week: Aussie dividend yields below 10-year average
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,144.70 | 189.80 | 2.12% |
| CAC 40 | 8,131.85 | 73.52 | -0.90% |
| DAX 40 | 25,799.91 | 525.10 | -1.99% |
| Dow JONES (US) | 51,470.23 | 52.83 | -0.10% |
| FTSE 100 | 10,645.39 | 137.27 | -1.27% |
| HKSE | 24,481.86 | 562.36 | 2.35% |
| NASDAQ | 24,615.59 | 300.60 | 1.24% |
| Nikkei 225 | 57,434.77 | 4,753.86 | -7.64% |
| NZX 50 Index | 13,998.50 | 92.47 | -0.66% |
| S&P 500 | 7,403.27 | 49.54 | 0.67% |
| S&P/ASX 200 | 9,020.80 | 186.30 | 2.11% |
| SSE Composite Index | 3,649.18 | 40.73 | -1.10% |